The endocannabinoid system targeted therapeutics market is projected to be over USD 5 billion by 2030, predicts Roots AnalysisSo far, more than 100 different cannabinoids have been identified, and the
So far, more than 100 different cannabinoids have been identified, and there is a growing body of evidence supporting the clinical benefits of this class of compounds in treating the symptoms of a wide variety of chronic health conditions
Roots Analysis is pleased to announce the publication of its recent study, titled, “Endocannabinoid System Targeted Therapeutics Market, 2020-2030.“
The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of endocannabinoid system targeting drugs, over the next decade. The report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain. In addition to other elements, the study includes:
- A detailed assessment of the current market landscape of drug developers engaged in the development of endocannabinoid system targeted therapeutics.
- Detailed profiles of developers of endocannabinoid system targeted therapeutics (shortlisted on the basis of the number of development programs).
- The geographical landscape of this industry is likely to evolve in the next few years as federal authorities legalize the use of medical cannabis across multiple countries
- Despite the associated stigma, many organizations have extended financial support to aid research efforts in this domain; the focus is on understanding the clinical benefits of endocannabinoid signaling in different diseases
- An in-depth analysis of nearly 600 grants that have been awarded to research institutes engaged in endocannabinoid system targeted therapeutics projects.
- An analysis of the partnerships that have been established in this domain, in the recent past.(shortlisted on the basis of the number of development programs)
- A detailed analysis of the various mergers and acquisitions that have taken place in this domain, between 2016-2020
- An insightful chessboard analysis highlighting the most popular drug development strategies / paths adopted by various drug developers in the domain of endocannabinoid system targeted therapeutics.
- A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
- Target Disease Indication
- Cancer
- Genetic Disorders
- Neurological Indications
- Others
- Route of Administration
- Oral
- Inhalation
- Key Geographies
- North America
- Europe
- Asia-Pacific and the Rest of the World
Key companies covered in the report
- GW Pharmaceuticals
- Corbus Pharmaceuticals
- Tilray
- Tetra Bio-Pharma
- Botanix Pharmaceuticals
- Kalytera Therapeutics
- Therapix Biosciences
- Echo Pharmaceuticals
- Avicanna
- GB Sciences
For more information please click on the following link:
https://www.rootsanalysis.com/reports/view_document/endocannabinoid-therapeutics/316.html
Other Recent Offerings
- Neoantigen Targeted Therapies Market, 2019-2030
- Blood-Brain Barrier (BBB) Market (2nd Edition), 2020-2030: Focus on Non-Invasive Drug Delivery Technology Platforms and Therapeutics
- Bispecific Antibody Therapeutics Market (4th Edition), 2019-2030
- Continuous Manufacturing Market (Small Molecules and Biologics), 2020 – 2030
Contact:
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
Gaurav.Chaudhary@rootsanalysis.com
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415